Sponsors (2)
The bill strengthens U.S. sanctions and financial tools to disrupt foreign facilitators and China-linked sources of illicit fentanyl—potentially reducing overdoses and protecting financial integrity—but relies on broad definitions and sanctioning authorities that raise compliance costs, risk harming legitimate businesses and individuals, and could strain international cooperation.
People in U.S. communities at risk of opioid overdose and law enforcement: the bill targets China-linked suppliers, precursors, and facilitators to disrupt fentanyl and synthetic opioid supply chains, which could reduce availability and overdose deaths.
U.S. agencies and taxpayers: the bill creates new authorities (asset freezes, sanctions, visa/entry restrictions, financial blocking) to disrupt and deter foreign facilitators of international illicit drug trafficking.
U.S. financial system and taxpayers: the bill protects financial system integrity by barring sanctioned foreign financial institutions from key roles (e.g., primary-dealer status or acting as U.S. Government agents/repositories), limiting abuse of U.S. financial channels.
Small businesses, multinational firms, and taxpayers: broad or expanded definitions (e.g., of 'United States person' and 'knowingly', including treating foreign branches as U.S. persons) increase legal exposure, compliance burdens, and operational/jurisdictional complications.
Legitimate businesses, intermediaries, and financial institutions: broad sanctions standards (e.g., 'knowingly or with reckless disregard') risk penalizing innocents and intermediaries, disrupting lawful commerce and marketplaces.
Banks, investors, and consumers: increased screening, blocked transactions, restrictions on investments and trade due to sanctions will raise compliance costs and could increase prices or reduce market opportunities for U.S. businesses and customers.
Based on analysis of 6 sections of legislative text.
Expands U.S. sanctions to prioritize and target PRC-linked persons and entities involved in producing, shipping, or facilitating fentanyl, precursors, and related equipment, adding financial, procurement, and visa penalties.
Introduced December 3, 2025 by Ben Ray Luján · Last progress December 3, 2025
Creates new and expanded U.S. sanctions tools to target people and companies tied to the People’s Republic of China that ship, produce, or otherwise facilitate fentanyl, fentanyl precursors, and related manufacturing equipment destined for Mexico or other countries that supply illicit fentanyl to the United States. It authorizes blocking, financial restrictions, procurement and banking prohibitions, and visa/entry bans, keeps existing Kingpin Act sanctions on major Mexican cartels, and sets a Dec. 31, 2030 sunset for one reporting provision. Most sanctions authorities can be used 180 days after enactment and rely on existing emergency economic powers; the bill also requires prioritizing identification of PRC-linked actors until China ceases to be the primary source and the President certifies that fact to Congress.